The use of golimumab in conjunction with discontinuation of previously used TNF-α antagonists resulted in sustained improvements in signs, symptoms, and physical functioning in patients with RA, primarily including improvements in the cardiovascular system and endothelial functioning, and reductions in arterial wall stiffness and atherosclerosis. Here, TNF is linked to rheumatoid arthritis.